Aileron Therapeutics' Phase 1b trial shows LTI-03 improved biomarkers and reduced SPD levels, indicating the potential to ...

The non-cystic fibrosis bronchiectasis market is driven by rising prevalence linked to respiratory infections, autoimmune diseases, and COPD. Increasing awareness among healthcare providers and ...

(RTTNews) - Aileron Therapeutics, Inc. (ALRN), Wednesday announced positive topline data from the cohort 2 of Phase 1b study evaluating LTI-03 in patients with idiopathic pulmonary fibrosis (IPF).

In a small Phase IIa trial, Insilico’s generative AI-designed idiopathic pulmonary fibrosis drug improved lung function and ...

Real World Study Compared Over 150,000 Adult & Pediatric Patients ––        Caldolor Associated with Fewer Adverse Drug Reactions ––        Caldolor also Improved Healthcare Utilization – This ...

A recent study showed that the COPD assessment test was reliable and responsive for assessing health status in fibrotic ...

What is cystic fibrosis liver disease? Liver disease associated with cystic fibrosis (CF) has been increasingly diagnosed during recent years, most likely due to the combined effect of systematic ...

When I was diagnosed with pulmonary hypertension (PH) at age 36, I was terrified. But then I remembered this wasn’t my first rodeo: I was born with sickle cell disease, and doctors said I wouldn ...

Department of Pediatrics, University of North Carolina, Chapel Hill, NC, USA Marsico Lung Institute, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA ...

You will be able to get a quick price and instant permission to reuse the content in many different ways. In sarcoidosis, fibrosis in affected organs, especially the lungs and heart, accounts for most ...